MERUS N.V. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.46 USD | -1.25% |
|
-0.11% | +61.71% |
| May. 13 | Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab | MT |
| May. 13 | Merus Carcinoma Treatment Awarded US FDA's Breakthrough Therapy Designation | DJ |
Presenter SpeechYigal Nochomovitz (Analysts)Okay. Great. Welcome back, everyone, to the Citi I...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
45.02
USD
Average target price
60.55
USD
Spread / Average Target
+34.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +61.71% | 2.64B | |
| +8.67% | 114B | |
| +11.13% | 104B | |
| -12.76% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.09% | 17.89B | |
| +7.87% | 14.28B | |
| +35.41% | 12.55B |
- Stock Market
- Equities
- MRUS Stock
- News Merus N.V.
- Transcript : Merus N.V. Presents at Citi’s 2022 Virtual Immuno-Oncology Summit, Feb-16-2022 01
